Literature DB >> 15510593

The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning.

Leslie Citrome1, Jan Volavka.   

Abstract

Five new antipsychotic drugs introduced in the United States in the last decade offer physicians the ability to treat patients with schizophrenia and bipolar mania without the adverse effects of the first-generation antipsychotics. In this article, the authors discuss the advantages and side effects of these agents and present a guide to help physicians choose the optimal drug in the most favorable formulation for each patient.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15510593     DOI： 10.3810/pgm.2004.10.1601

Source DB:  PubMed          Journal:  Postgrad Med        ISSN： 0032-5481            Impact factor:   3.840


  5 in total

Review 1.  Aripiprazole in acute mania and long-term treatment of bipolar disorder: a critical review by an Italian working group.

Authors:  Pasquale De Fazio; Paolo Girardi; Giuseppe Maina; Massimo Carlo Mauri; Mauro Mauri; Palmiero Monteleone; Giulia Ida Perini; Giulio Perugi; Alessandro Rossi
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

Review 2.  [Pharmacotherapy for schizophrenia].

Authors:  W W Fleischhacker; W Hummer
Journal:  Nervenarzt       Date:  2006-11       Impact factor: 1.214

3.  QT prolongation and Torsades de Pointes following overdose of ziprasidone and amantadine.

Authors:  Alex F Manini; Dara Raspberry; Robert S Hoffman; Lewis S Nelson
Journal:  J Med Toxicol       Date:  2007-12

4.  Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized, placebo-controlled trial in clinically stable patients.

Authors:  Joseph Peuskens; Jitendra Trivedi; Sergiy Malyarov; Martin Brecher; Ola Svensson; Frank Miller; Inger Persson; Didier Meulien
Journal:  Psychiatry (Edgmont)       Date:  2007-11

5.  Acute peripheral but not central administration of olanzapine induces hyperglycemia associated with hepatic and extra-hepatic insulin resistance.

Authors:  Elodie M Girault; Anneke Alkemade; Ewout Foppen; Mariëtte T Ackermans; Eric Fliers; Andries Kalsbeek
Journal:  PLoS One       Date:  2012-08-14       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.